---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-024556"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2026-06-09T11:16:42+00:00"
generated_at: "2026-06-09T11:22:08.955508+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cartesian licenses WestGene's in vivo CAR-T LNP platform for autoimmune diseases; MG trial starts 2H2026

## Summary
- WestGene receives upfront payment and milestone-based payments; Cartesian gains exclusive rights to WestGene's tLNP platform for in vivo CAR-T.
- Phase 1 dose-escalation study of Descartes-08 mRNA delivered via WestGene's tLNPs in generalized myasthenia gravis expected to begin 2H 2026.
- In-human proof-of-concept data expected in 1H 2027; Cartesian plans to advance additional anti-BCMA CAR constructs and a BCMA TCE.
- WestGene's prior clinical data showed no DLTs, SAEs, ICANS, or IRRs in up to 14 doses per patient; only Grade 1 CRS observed.

## SEC filing metadata
- accession: 0001140361-26-024556
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2026-06-09T11:16:42+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000114036126024556/0001140361-26-024556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000114036126024556/ef20075770_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-024556
- JSON: https://secwatch.observer/filing/0001140361-26-024556.json
- Plain text: https://secwatch.observer/filing/0001140361-26-024556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.